Visual and refractive outcomes in hyperopic pseudophakic patients implanted with a trifocal intraocular lens
Session Details
Session Title: Multifocal IOLs I
Session Date/Time: Sunday 15/09/2019 | 16:30-18:00
Paper Time: 17:18
Venue: Free Paper Forum: Podium 1
First Author: : C.Fernandez SPAIN
Co Author(s): : L. Fernandez-Vega-Cueto B. Alfonso-Bartolozzi R. Montes-Mico J. Alfonso
Abstract Details
Purpose:
To assess visual and refractive results after bilateral implantation of a trifocal intraocular lens (IOL) in patients wit hyperopia.
Setting:
Instituto Universitario Fernandez-Vega
Methods:
In a retrospective non-randomized study, 196 eyes of 98 patients had bilateral implantation of the PanOptix trifocal IOL. The Barrett Universal II formula was used for IOL power calculation. Eyes were divided in two groups for their analysis: low-moderate, with IOL power ranging from 22 to 26 D, and high, with IOL power ranging from 25 to 34 D. Refractive error was used to assess predictability, and corrected distance visual acuity (CDVA) and uncorrected distance visual acuity values were used to assess efficacy and safety of the surgery.
Results:
Six months postoperatively our results revealed a Snellen CDVA of 0.97±0.05 and 0.94±0.09, for the low-moderate and high group, respectively. The low-moderate group showed a 75.23% of eyes with 20/20 of CDVA and 100% eyes with 20/25 of CDVA, and the high hyperopia group showed percentages of 60.95 and 94.29 for these values of VA, respectively. The mean postoperative spherical equivalent was -0.25±0.36D and -0.24±0.42D for low-moderate and high hyperopia groups, respectively. In case of low-moderate 81% eyes were within ±0.50D and 99% within ±1.00D. These values were 78% and 95%, for the high hyperopic eyes
Conclusions:
Bilateral implantation of the AcrySof IQ PanOptix trifocal IOL in hyperopic eyes provided good visual and refractive outcomes. The Barrett Universal II formula was accurate predicting the IOL power in hyperopic eyes.
Financial Disclosure:
None
